Jane S. Ricciuti, RPh, MS


June 11, 2004

In This Article


The US Food and Drug Administration (FDA) approved Vidaza (azacitidine) as an orphan drug for the treatment of patients with myelodysplastic syndrome. Additional oncology drug approvals include new indications for Gemzar (gemcitabine), Iressa (gefitinib), and Taxotere (docetaxel).

This month's column reviews FDA new product approvals and labeling changes for:

Analgesic Agents

  • DepoDur (morphine sulfate extended-release liposome) Injection

Anti-Infective Agents

  • Avelox (moxifloxacin) Tablets and Injection

Antineoplastic Agents

  • Gemzar (gemcitabine) Injection

  • Iressa (gefitinib) Tablets

  • Taxotere (docetaxel) Injection

  • Vidaza (azacitidine) Injection

Surgical Agents

  • Vitrase (hyaluronidase) Injection


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.